Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Defensin beta 117 (DEFB117) is an annotated beta-defensin family gene, presumed to encode a small, cationic antimicrobial peptide. Beta-defensins are characterized by a set of conserved cysteine residues that form three disulfide bonds, imparting a stable, compact structure[1][3]. While other beta-defensins participate broadly in innate immunity, epithelial defense, and sometimes immune cell chemotaxis, there is no published evidence describing the expression, structure, molecular interactions, functional roles, or disease relevance of DEFB117 specifically. No data exists regarding druggability or clinical targeting of DEFB117. This target should be considered an orphan annotation with no substantiated molecular, biomedical, or therapeutic relevance at the present time[1][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Defensin beta 117 (DEFB117).